Grifols, S.A. (BME:GRF)
9.18
+0.09 (1.01%)
May 18, 2026, 4:25 PM CET
Grifols Revenue
Grifols had revenue of 1.70B EUR in the quarter ending March 31, 2026, a decrease of -4.81%. This brings the company's revenue in the last twelve months to 7.44B, up 0.89% year-over-year. In the year 2025, Grifols had annual revenue of 7.52B with 4.33% growth.
Revenue (ttm)
7.44B
Revenue Growth
+0.89%
P/S Ratio
0.75
Revenue / Employee
297.52K
Employees
25,000
Market Cap
5.57B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.52B | 312.00M | 4.33% |
| Dec 31, 2024 | 7.21B | 620.00M | 9.41% |
| Dec 31, 2023 | 6.59B | 528.03M | 8.71% |
| Jan 1, 2023 | 6.06B | 1.13B | 22.92% |
| Dec 31, 2021 | 4.93B | -406.92M | -7.62% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Almirall | 1.12B |
| Laboratorios Farmaceuticos Rovi | 741.09M |
| Faes Farma | 674.06M |
| Laboratorio Reig Jofre | 335.01M |
| Clínica Baviera | 304.91M |
| Prim, S.A. | 251.89M |
| Pharma Mar | 225.43M |
| Atrys Health | 144.31M |
Grifols News
- 6 weeks ago - Ban Grifols and return plasma collection to Canadian Blood Services and Héma-Québec, say health care advocates - GlobeNewsWire
- 7 weeks ago - Grifols approves IPO of its US biopharma business - Reuters
- 2 months ago - Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson's Disease - GlobeNewsWire
- 2 months ago - Health Coalition demands disclosures & end to Grifols' for-profit blood plasma contract following reports of deaths, harm, non-compliance - GlobeNewsWire
- 2 months ago - Media Advisory: Press Conference Regarding Tragic Deaths After Plasma Harvesting at Grifols' Sites - GlobeNewsWire
- 2 months ago - Grifols doubles net profit in 2025, driven by revenues - Reuters
- 7 months ago - Spanish court summons Gotham City founder in Grifols share price probe - Reuters
- 1 year ago - XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology - GlobeNewsWire